Thrivent Financial for Lutherans Sells 17,146 Shares of LivaNova PLC (NASDAQ:LIVN)

Thrivent Financial for Lutherans decreased its position in LivaNova PLC (NASDAQ:LIVN) by 57.3% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 12,757 shares of the company’s stock after selling 17,146 shares during the period. Thrivent Financial for Lutherans’ holdings in LivaNova were worth $670,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in LIVN. Point72 Asset Management L.P. raised its holdings in LivaNova by 204.3% in the 2nd quarter. Point72 Asset Management L.P. now owns 1,285,636 shares of the company’s stock valued at $70,479,000 after acquiring an additional 863,157 shares in the last quarter. First Light Asset Management LLC raised its holdings in LivaNova by 591.1% in the 2nd quarter. First Light Asset Management LLC now owns 710,390 shares of the company’s stock valued at $38,944,000 after acquiring an additional 607,598 shares in the last quarter. Great Lakes Advisors LLC acquired a new position in LivaNova in the 2nd quarter valued at approximately $16,614,000. Driehaus Capital Management LLC raised its holdings in LivaNova by 64.7% in the 2nd quarter. Driehaus Capital Management LLC now owns 544,042 shares of the company’s stock valued at $29,824,000 after acquiring an additional 213,749 shares in the last quarter. Finally, Perceptive Advisors LLC raised its holdings in LivaNova by 48.5% in the 2nd quarter. Perceptive Advisors LLC now owns 444,000 shares of the company’s stock valued at $24,340,000 after acquiring an additional 145,000 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on LIVN. Baird R W raised LivaNova from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 17th. StockNews.com cut LivaNova from a “strong-buy” rating to a “buy” rating in a report on Saturday, November 16th. Robert W. Baird increased their target price on LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. Mizuho dropped their target price on LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a report on Thursday, October 31st. Finally, Needham & Company LLC reissued a “buy” rating and issued a $75.00 target price on shares of LivaNova in a report on Monday, November 25th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $69.17.

LivaNova Stock Down 0.8 %

NASDAQ LIVN opened at $51.19 on Thursday. The firm has a market cap of $2.78 billion, a PE ratio of 121.88 and a beta of 0.98. LivaNova PLC has a one year low of $42.75 and a one year high of $64.47. The stock’s 50 day simple moving average is $52.28 and its 200 day simple moving average is $51.95. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.